Go or no go? Aducanumab’s day of reckoning

Go or no go? Aducanumab’s day of reckoning

Submitted by admin on May 27, 2021 - 10:56am
Source: 
EP Vantage
News Tags: 
Biogen
FDA
aducanumab
Ascendis Pharma
Novo Nordisk
TransCon hGH
semaglutide
Headline: 
Go or no go? Aducanumab’s day of reckoning
snippet: 

Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.

Do Not Allow Advertisers to Use My Personal information